Table 1.
Observed differences among MSM and TGs (N = 176)
| Before | After | Beforea | Aftera | Mean difference | |
|---|---|---|---|---|---|
| N | N | Mean (SD) | Mean (SD) | ||
| Outcomes | |||||
| Future attendance at HIV vaccine activities | 77 | 85 | 8.57 (2.00) | 8.00 (2.52) | −0.57 |
| Community mobilization | 78 | 83 | 5.60 (2.94) | 5.55 (3.05) | −0.05 |
| Study screen | 77 | 80 | 4.29 (3.32) | 5.36 (3.40) | 1.07* |
| Study enrollment | 71 | 79 | 3.94 (3.12) | 5.09 (3.43) | 1.15* |
| HIV vaccine research promotion in community | 76 | 85 | 6.46 (3.19) | 6.34 (3.02) | −0.12 |
| Community engagement factors | |||||
| Attitudes | 79 | 88 | 8.47 (2.52) | 8.43 (3.31) | −0.04 |
| Behavioral beliefs | 77 | 86 | 12.97 (4.10) | 12.43 (4.82) | −0.54 |
| Outcome evaluation (risk perception) | 80 | 91 | 17.49 (4.29) | 16.49 (4.79) | 1.00 |
| Organizational involvement (study-site assessment) | 79 | 88 | 10.33 (2.66) | 9.65 (2.61) | −0.68 |
| Social activism congruence | 80 | 85 | 16.06 (4.01) | 16.18 (4.83) | 0.12 |
*
P < 0.05.
a
“Before” data collected prior to 21 September 2007. “After” data collected subsequent to 22 September 2007.
Abbreviations: MSM, men-who-have-sex-with-men; TGs, transgenders; SD, standard deviation; HIV, human immunodeficiency virus.